AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00737360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-106
Description: 6.5 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
Study NCT01911260 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Zinc amino acid chelate
Description: During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
Study NCT01911260 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
Study NCT03270995 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Existential Therapy Group 1
Description: Six group sessions of two hour each using a cognitive-existential group approach
Study NCT03270995 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy Group 2
Description: Six group session of two hour each using a supportive group approach.
Study NCT03236545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No to Low Endogenous Estrogen
Description: Ganirelix acetate (Antagon) will be used to prevent endogenous production of ovarian hormones in young women. Ganirelix is derived from native GnRH, and acts by competitively blocking GnRH receptors on the pituitary and subsequent pathways. Thus, administration of the GnRH antagonist (GnRHant) suppresses steroidogenesis, leading to low or undetectable serum estrogen and progesterone concentrations, which occurs within two days of initiation of administration (Oberye, Mannaerts, Huisman \& Timmer, 1999; Oberye, Mannaerts, Kleijn, \& Timmer, 1999).
Study NCT03236545 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Estradiol
Description: Short term estradiol administration elicits changes in vascular function in women, and 0.1mg/day patch is the upper recommended limit for hormone therapy in women (Wenner, Taylor, \& Stachenfeld, 2011; Moreau, Hildreth, Meditz, Deane \& Kohrt, 2012).
Study NCT03925467 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Proximal acupoints: disposable acupuncture needles will be inserted into acupoints (GB34, SP9, EX-LE2) bilaterally for a depth of 10-30 mm.~Distal acupoints: disposable acupuncture needles will be inserted into acupoints (LI11, HT3, TE10) bilaterally for a depth of 10-30 mm.~Sham acupoints: Sham acupuncture needles will be administered into sham acupoints RN12, ST21.
Study NCT03925467 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acupuncture
Description: Proximal acupoints: disposable acupuncture needles will be inserted into acupoints (GB34, SP9, EX-LE2) bilaterally for a depth of 10-30 mm.~Distal acupoints: disposable acupuncture needles will be inserted into acupoints (LI11, HT3, TE10) bilaterally for a depth of 10-30 mm.~Sham acupoints: Sham acupuncture needles will be administered into sham acupoints RN12, ST21.
Study NCT00741377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHQ880
Study NCT00741377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Study NCT00209131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flomax
Description: 0.4mg Flomax pills will be given to patients to take once daily for one month following shock wave lithotripsy to aid the stone passage.
Study NCT00209131 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Comparable sugar pills will be given to the placebo group to take daily for one month following shock wave lithotripsy to aid stone passage.
Study NCT05728021 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery Record Aftercare
Description: Patients randomized to IG receive a therapist-guided smartphone-based aftercare intervention for a period of 16 weeks. The patients are invited to download for free the German version of Recovery Record at the App Store (iPhone) or the Google Play Store (android) to their smartphone and to link with the aftercare therapist. After discharge, patients are asked to monitor their meals at least three times per day (breakfast, lunch, and dinner), that is, to produce a minimum of three logs per day over the subsequent 16 weeks. Furthermore, patients are instructed to monitor their thoughts and feelings as well as their (eating disordered) behaviors. The aftercare therapist also sets the patients clinical post-discharge goals and makes coping skill suggestions. Individual therapist feedback is provided in-app twice per week during the first four weeks, once per week in weeks 5-8 and every other week in weeks 9-16.
Study NCT05728021 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: Patients randomized to CG receive TAU i.e. patients and their physicians or therapists decide on post-discharge treatment which is documented at T1 and T2. Patients from the CG are also assessed at all assessment points.
Study NCT02401022 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD8529
Description: comparison of different dosages of drug
Study NCT03477136 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA to evaluate serum and seminal vitamin D level
Description: Serum and semen samples will be collected from all participant males and ELISA method used to evaluate the level of vitamin D in serum and semen
Study NCT03417323 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Compression
Description: Participants in the treatment group wear compression garment after intense WB-EMS application for 24 h, and 12 h for day 2, 3, 4 post WB-EMS.
Study NCT03117920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minnelide
Description: Minnelide will be administered at the dose of 0.67 mg/m2 as a 30 min infusion intravenously daily on days 1-21 of each cycle followed by a 7 day rest period (days 22-28).
Study NCT02043080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF Tuberculosis diagnostic tool
Description: This is s new diagnostic tool that has been approved by WHO for the diagnosis of TB in HIV-infected patients in resource limited settings
Study NCT00651391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Simvastatin
Description: oral tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily in the evening for 12 weeks
Study NCT00651391 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: oral simvastatin 20 mg once daily in the evening for 12 weeks
Study NCT00651391 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral placebo once daily in the evening for 12 weeks
Study NCT02564497 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Process E Belatacept
Study NCT02564497 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Process C Belatacept
Study NCT02904993 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: L2 paravertebral block
Description: nerve block group will receive preoperatively a L2 paravertebral block with indwelling catheter
Study NCT02904993 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: periarticular injection group
Description: periarticular injection group will receive the injection cocktail towards the end of the total hip replacement prior to skin closure.
Study NCT01518348 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Patch Test
Description: Patch Tested with Gold sodium thiosulfate, 0.075 mg/cm2 in hydroxypropylcellulose · Hydrocortisone-17-butyrate, 0.020 mg/cm2 in polyvinylpyrrolidone· Methyldibromoglutaronitrile, 0.0053 mg/cm2 in polyvinylpyrrolidone·Bacitracin, 0.60 mg/cm2 in hydroxypropylcellulose· Parthenolide, 0.0030 mg/cm2 in polyvinylpyrrolidone· Disperse blue 106, 0.050 mg/cm2 in polyvinylpyrrolidone· Bronopol, 0.25 mg/cm2 in polyvinylpyrrolidone
Study NCT03918148 — intervention group
Intervention type: DRUG
Intervention: SGLT-2i
Description: Dapagliflozin or canagliflozin or empagliflozin add on to metformin ± basal insulin
Study NCT03918148 — intervention group
Intervention type: DRUG
Intervention: DPP-4i
Description: Sitagliptin or vildagliptin or saxagliptin or linagliptin or alogliptin add on to metformin ± basal insulin
Study NCT02949700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin will be administered orally twice daily during treatment with chemo-radiation for head and neck squamous cell carcinoma. This will occur 7 to 11 days prior to chemotherapy and radiation.
Study NCT04128085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3804
Description: A kind of tyrosine kinase inhibitor.
Study NCT02187744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-05280014
Description: Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum of 6 cycles.
Study NCT02187744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taxotere®
Description: Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
Study NCT02187744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paraplatin®
Description: Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
Study NCT02187744 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab-EU
Description: Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum 6 cycles.
Study NCT02187744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taxotere®
Description: Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
Study NCT02187744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paraplatin®
Description: Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
Study NCT02358681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac, intranasal
Description: Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route.
Study NCT02358681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac, intravenous
Description: Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route.
Study NCT02358681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo, intravenous
Description: Placebo of equal volume to IV ketorolac, to be administered by intravenous route.
Study NCT02358681 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo, intranasal
Description: Placebo of equal volume to IN ketorolac, to be administered by intranasal route.
Study NCT02067130 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fibroscan
Description: Transient elastography (Fibroscan®) is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Since Fibroscan® measures liver's stiffness, its utility is not limited to fibrosis, and has been extended to other conditions that would increase the liver's stiffness, such as amyloidosis (Loustaud-Ratti et al. Amyloid 2011) and perhaps iron overload.
Study NCT00169793 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: evaluation of kidney stone risk after bariatric surgery
Description: 24 hour urine collections done pre and post surgery
Study NCT00169793 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluate risk of kidney stones after bariatric surgery
Description: 24 hour urine collections are done before and after surgery
Study NCT03244605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation Training
Description: Patients will be trained in one month after operation. Rehabilitation training include aerobic exercise training (using cycle ergometer for 7-14 times at all, once a day, 15-20 min/time and using treadmill for 7-14 times at all, once a day, 15-20 min/time according to the patient's endurance) and Liu Zi Jue lung exercises, which strengthen the lung function of the human body in Chinese traditional health culture, five times a week, 15 min/time.
Study NCT00855673 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Mechanical Compression
Description: FM220 device
Study NCT00855673 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard medical treatment
Study NCT06081712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198
Description: TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
Study NCT06081712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNP-2198 Placebo
Description: TNP-2198 capsules/placebo were administered orally twice daily (BID, at 7:00 ± 1 hour in the morning and 19:00 ± 1 hour in the evening) in the fasted state for consecutive 14 days, and the last dose was taken at 7:00 am (±1 hour) on Day 15 in the fasted state, and breakfast or dinner should not be taken within 30 minutes after each dose.
Study NCT02741856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: For more information please see the arm descriptions section.
Study NCT02741856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: For more information please see the arm descriptions section.
Study NCT02741856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: For more information please see the arm descriptions section.
Study NCT02741856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: For more information please see the arm descriptions section.
Study NCT02741856 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: For more information please see the arm descriptions section.
Study NCT00285233 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic islets of Langerhans transplant
Description: Allogeneic islets of Langerhans transplant
Study NCT04548583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remestemcel-L
Description: adult allogeneic bone marrow derived mesenchymal stem cell product for the treatment of medically refractory Crohn's colitis
Study NCT04548583 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT03726944 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Calm App Meditation
Description: The Calm app intervention consisted of 10 min/day of meditation for 4 weeks via the Calm smartphone app.
Study NCT03726944 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Unnamed Consumer-Based App Meditation
Description: The unnamed consumer-based app intervention consisted of 10 min/day of meditation for 4 weeks via an unnamed consumer-based meditation smartphone app.
Study NCT03726944 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Educational Control
Description: The educational control consisted of an educational handout that was provided to participants. This control lasted for 4 weeks.
Study NCT02416570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Study NCT02416570 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02236403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin 0.1% Metronidazole 1%
Study NCT02236403 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: None intervention
Description: Volunteers with no signs of blepharitis and with eyelashes with no demodex. Symptoms and signs will be compared with experimental group
Study NCT03351933 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin (Human)
Description: A single 0.2 mL/kg IM injection of Immune Globulin (Human) (GamaSTAN) was administered in healthy subjects.
Study NCT02586129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH14755
Description: 20/1500mg, QD
Study NCT02586129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: 1500mg, QD
Study NCT02586129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 20mg, QD
Study NCT03766074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D supplement
Description: The intervention group receives 50000 IU of vitamin D every 2 weeks as vitamin D supplements for 8 weeks, provided monthly.
Study NCT03766074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT03406767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GLA:D Canada Program
Description: The GLA:D® program consists of 1) pre- and post-program outcome measurement (self-reported and functional outcomes); 2) 2, 1-1.5 hour education sessions including information on OA disease characteristics, treatments and self-help strategies; and 3) a neuromuscular exercise (warm-up, circuit training, and cool down) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks. The goal of the exercises is to restore neutral, functional alignment of the legs by building compensatory functional stability and improving sensorimotor control.
Study NCT03406767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: JointEffort Program
Description: The JointEffort program consists of: 1) one appointment aimed at individualized program design (1-1.5 hours); 2) a nutritional seminar taught by a registered dietician explaining dietary recommendations for OA patients and inflammatory conditions, including weight loss and/or management (1 hours); and 3) an individualized exercise (strength and neuromuscular training, balance training, and range of motion exercises) training program administered in 1 hour, small (up to 10 persons) group-based, supervised sessions twice weekly for 6 weeks.
Study NCT03748784 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADVM-022
Description: ADVM-022 (AAV.7m8-aflibercept) is a recombinant, replication-deficient adeno-associated virus (AAV.7m8) gene therapy vector carrying a coding sequence for aflibercept
Study NCT00929591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Study NCT00929591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endocrine therapy
Study NCT00929591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endocrine therapy
Study NCT00929591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: endocrine-modulating drug therapy
Study NCT00929591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00929591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Study NCT00929591 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tamoxifen citrate
Study NCT00929591 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: brachytherapy
Study NCT00929591 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: brachytherapy
Study NCT00929591 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy
Study NCT00929591 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET electron therapy
Study NCT00929591 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study NCT00929591 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: low-LET photon therapy
Study NCT00929591 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy